Literature DB >> 18945384

Invasive opportunistic mycoses: clinical trials review, 2007-2008.

Andreas H Groll1.   

Abstract

Invasive fungal infections are important causes of morbidity and mortality in severely ill patients. The past decade has seen considerable expansion in the development of new antifungal compounds, and clinical trials continue to define their role in our antifungal armamentarium. This brief article summarizes the most pivotal clinical trials in the settings of treatment and prophylaxis of invasive opportunistic mycoses published between 2007 and 2008.

Entities:  

Year:  2008        PMID： 18945384     DOI： 10.1007/s11908-008-0073-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  11 in total

1.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

2.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

3.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).

Authors:  Oliver A Cornely; Johan Maertens; Mark Bresnik; Ramin Ebrahimi; Andrew J Ullmann; Emilio Bouza; Claus Peter Heussel; Olivier Lortholary; Christina Rieger; Angelika Boehme; Mickael Aoun; Heinz-August Horst; Anne Thiebaut; Markus Ruhnke; Dietmar Reichert; Nicola Vianelli; Stefan W Krause; Eduardo Olavarria; Raoul Herbrecht
Journal:  Clin Infect Dis       Date:  2007-04-09       Impact factor: 9.079

4.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

5.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

6.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

Authors:  Ernst-Rüdiger Kuse; Ploenchan Chetchotisakd; Clovis Arns da Cunha; Markus Ruhnke; Carlos Barrios; Digumarti Raghunadharao; Jagdev Singh Sekhon; Antonio Freire; Venkatasubramanian Ramasubramanian; Ignace Demeyer; Marcio Nucci; Amorn Leelarasamee; Frédérique Jacobs; Johan Decruyenaere; Didier Pittet; Andrew J Ullmann; Luis Ostrosky-Zeichner; Olivier Lortholary; Sonja Koblinger; Heike Diekmann-Berndt; Oliver A Cornely
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

7.  Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Authors:  Peter G Pappas; Coleman M F Rotstein; Robert F Betts; Marcio Nucci; Deepak Talwar; Jan J De Waele; Jose A Vazquez; Bertrand F Dupont; David L Horn; Luis Ostrosky-Zeichner; Annette C Reboli; Byungse Suh; Raghunadharao Digumarti; Chunzhang Wu; Laura L Kovanda; Leah J Arnold; Donald N Buell
Journal:  Clin Infect Dis       Date:  2007-08-29       Impact factor: 9.079

8.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

Authors:  M A Slavin; B Osborne; R Adams; M J Levenstein; H G Schoch; A R Feldman; J D Meyers; R A Bowden
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

9.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

10.  Caspofungin for the treatment of less common forms of invasive candidiasis.

Authors:  Oliver A Cornely; Martin Lasso; Robert Betts; Nickolay Klimko; Jose Vazquez; Geoff Dobb; Juan Velez; Angela Williams-Diaz; Joy Lipka; Arlene Taylor; Carole Sable; Nicholas Kartsonis
Journal:  J Antimicrob Chemother       Date:  2007-05-26       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.